A new report from FirstWord spotlights the payer perspective on the “sluggish” U.S. biosimilar market, including payer insights on current trends and how the pharmaceutical industry could move forward.
“Originator companies are fiercely defending their brands which has slowed new product introductions and limited clinicians’ ability to build prescribing confidence with biosimilar products,” a description of the report states.
To learn more about this report from FirstWord, click here.
